Source: International Congress 2018 – Pharmacological management of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Ferguson (Farmington Hills, United States of America), A. Papi (Ferrara, Italy), A. Anzueto (San Antonio, United States of America), E. Kerwin (Medford, United States of America), C. Cappelletti (Durham, United States of America), E. Duncan (Durham, United States of America), J. Nyberg (Morristown, United States of America), P. Dorinsky (Durham, United States of America). Efficacy and safety of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) using co-suspension delivery technology compared to monocomponents and an active comparator in COPD. 775

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD Source: ERJ Open Res, 6 (2) 00187-2019; 10.1183/23120541.00187-2019 Year: 2020 Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002 Efficacy and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (GFF MDI) delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe COPD Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018 A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001 Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003 Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001 Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020 Comparison of the long-term efficacy and safety of ipratropium bromide (IB) delivered by a new soft mist inhaler (SMI) versus conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 69s Year: 2001 Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001 Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002 Assessment of relative potency of salbutamol administered via a metered-dose inhaler plus spacer or via a dry-powder inhaler in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 209s Year: 2006 Improvement in the drug delivery of salmeterol/fluticasone via a novel breath actuatedpressurized metered dose inhaler with a dose counter Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019 Efficacy of salmeterol/fluticasone propionate combination administered via Diskus inhaler in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002 Salmeterol metered dose inhaler (MDI) propelled by hydrofluoroalkane (HFA) is non-inferior to salmeterol chlorofluorocarbon (CFC) propelled MDI in paediatic patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004 Pharmaceutical development of salmeterol HFA metered dose inhaler Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004 Comparison of the efficacy and safety of budesonide administered via Clickhaler® or Turbuhaler® Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003 Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004